Retatrutide vs Tirzepatide vs Semaglutide: Key Differences

Retatrutide, tirzepatide and semaglutide often appear in the same research context, but they are different molecules and do not act on the same number of receptor systems. Their receptor profiles are the key distinction.

Semaglutide: a GLP-1 receptor agonist

Semaglutide acts as a GLP-1 receptor agonist. Regulated pharmaceutical products containing semaglutide have extensive clinical documentation, but those data do not establish the properties of any separate research material. The FDA describes semaglutide as a GLP-1 analogue that selectively activates the GLP-1 receptor.

FDA documentation for semaglutide

Tirzepatide: GIP + GLP-1

Tirzepatide activates two receptor systems: the GIP receptor and the GLP-1 receptor. This dual profile distinguishes it from semaglutide, which targets the GLP-1 receptor.

FDA documentation for tirzepatide

Retatrutide: GIP + GLP-1 + glucagon receptor

Retatrutide is an investigational triple agonist that activates GIP, GLP-1 and glucagon receptors. Lilly continues to describe it as an investigational molecule, and positive results from several phase 3 trials were announced in 2026. At present, the molecule is not approved for public use.

Lilly: retatrutide's status and mechanism

Comparing receptor profiles

Why more receptors do not mean a “better” compound

Targeting more receptors does not automatically make a molecule better, safer or more suitable for a particular purpose. The receptor profile describes the mechanism; clinical efficacy, safety, formulation and regulatory status are separate questions.

Connecting this to the research catalogue

For a broader overview, see metabolic and incretin signalling and the individual profiles for Retatrutide, Tirzepatide and Semaglutide.

This content provides educational and research context. It is not medical advice, a treatment recommendation or instructions for use in humans or animals.